BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026 - 2Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- 3French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- 4Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- 5'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more
- High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- Vote in favor of your Favored sort of footwear
- Nations for Youngsters to Visit
- Rick Steves' Newest Guidebook Is A Fresh Perspective On Italy Spilling The Country's Secrets
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- Miss Thailand Pageant Contestant's Veneers Fall Out During Speech on Stage
- They relied on marijuana to get through the day. But then days felt impossible without it
- Choosing the Ideal Bed for Quality Rest and Solace
- Parents who delay baby's first vaccines also likely to skip measles shots
